BAYER HEALTHCARE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER HEALTHCARE, and when can generic versions of BAYER HEALTHCARE drugs launch?
BAYER HEALTHCARE has twenty-nine approved drugs.
There are twenty-eight US patents protecting BAYER HEALTHCARE drugs. There is one tentative approval on BAYER HEALTHCARE drugs.
There are four hundred and twenty-nine patent family members on BAYER HEALTHCARE drugs in fifty-nine countries and fifty supplementary protection certificates in seventeen countries.
Summary for BAYER HEALTHCARE
| International Patents: | 429 |
| US Patents: | 28 |
| Tradenames: | 24 |
| Ingredients: | 14 |
| NDAs: | 29 |
| Patent Litigation for BAYER HEALTHCARE: | See patent lawsuits for BAYER HEALTHCARE |
Drugs and US Patents for BAYER HEALTHCARE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | OCUCLEAR | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 018471-001 | May 30, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-002 | Aug 6, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099-001 | Jul 30, 2019 | RX | Yes | Yes | 11,168,058 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Bayer Healthcare Llc | CLARITIN | loratadine | SYRUP;ORAL | 020641-002 | Nov 27, 2002 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Bayer Healthcare Llc | GYNE-LOTRIMIN 3 COMBINATION PACK | clotrimazole | CREAM, TABLET;TOPICAL, VAGINAL | 020526-002 | Jul 29, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 8,865,698 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAYER HEALTHCARE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | CLARITIN-D 24 HOUR | loratadine; pseudoephedrine sulfate | TABLET, EXTENDED RELEASE;ORAL | 020470-002 | Nov 27, 2002 | 4,659,716*PED | ⤷ Sign Up |
| Bayer Healthcare Llc | CLARITIN | loratadine | SYRUP;ORAL | 020641-002 | Nov 27, 2002 | 6,132,758 | ⤷ Sign Up |
| Bayer Healthcare Llc | CLARITIN | loratadine | SYRUP;ORAL | 020641-002 | Nov 27, 2002 | 4,863,931*PED | ⤷ Sign Up |
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | 7,511,041 | ⤷ Sign Up |
| Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-002 | Nov 27, 2002 | 4,863,931*PED | ⤷ Sign Up |
| Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-002 | Nov 27, 2002 | 4,659,716*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BAYER HEALTHCARE Drugs
Supplementary Protection Certificates for BAYER HEALTHCARE Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2493858 | 122020000030 | Germany | ⤷ Sign Up | PRODUCT NAME: DAROLUTAMID; NAT. REGISTRATION NO/DATE: EU/1/20/1432 20200327; FIRST REGISTRATION: EU EU/ 1/2011432 20200327 |
| 2493858 | 2090018-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: DAROLUTAMIDE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/20/1432/001 20200330 |
| 2493858 | C02493858/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: DAROLUTAMIDUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67521 19.06.2020 |
| 3141251 | 301099 | Netherlands | ⤷ Sign Up | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
| 3106463 | CA 2020 00013 | Denmark | ⤷ Sign Up | PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923 |
| 2493858 | 2020/018 | Ireland | ⤷ Sign Up | PRODUCT NAME: DAROLUTAMIDE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/20/1432/001 20200330 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
